During the last session, Xeris Biopharma Holdings Inc (NASDAQ:XERS)’s traded shares were 0.86 million, with the beta value of the company hitting 1.67. At the end of the trading day, the stock’s price was $1.75, reflecting an intraday gain of 2.94% or $0.05. The 52-week high for the XERS share is $3.26, that puts it down -86.29 from that peak though still a striking 16.57% gain since the share price plummeted to a 52-week low of $1.46. The company’s market capitalization is $259.44M, and the average trade volume was 1.89 million shares over the past three months.
Xeris Biopharma Holdings Inc (NASDAQ:XERS) trade information
Xeris Biopharma Holdings Inc (XERS) registered a 2.94% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 2.94% in intraday trading to $1.75, hitting a weekly high. The stock’s 5-day price performance is 0.57%, and it has moved by -14.22% in 30 days. Based on these gigs, the overall price performance for the year is -19.35%.
Xeris Biopharma Holdings Inc (XERS) estimates and forecasts
Statistics show that Xeris Biopharma Holdings Inc has outperformed its competitors in share price, compared to the industry in which it operates. Xeris Biopharma Holdings Inc (XERS) shares have gone up 1.16% during the last six months, with a year-to-date growth rate more than the industry average at 15.56% against 10.40. In the rating firms’ projections, revenue will increase 12.50% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 41.81M as predicted by 6 analyst(s). Meanwhile, a consensus of 6 analyst(s) estimates revenue growth to 45.1M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 33.2M and 38.01M respectively. In this case, analysts expect current quarter sales to grow by 25.90% and then jump by 18.70% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 38.13%. While earnings are projected to return 23.17% in 2024.
XERS Dividends
Xeris Biopharma Holdings Inc is due to release its next quarterly earnings in May. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
